文献检索，用中文搜 PubMed

Gilead Sciences will buy Kite Pharma-and its autologous CAR T-cell technology-for $11.9 billion. The acquisition will help Gilead build its oncology portfolio and boost its revenues.

吉利德科学公司将以 119 亿美元收购 Kite 制药公司及其自体 CAR-T 细胞技术。此次收购将帮助吉利德科学公司建立其肿瘤学产品组合，并提高其收入。

Gilead Sciences will buy Kite Pharma-and its autologous CAR T-cell technology-for $11.9 billion. The acquisition will help Gilead build its oncology portfolio and boost its revenues.